Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
==== Cleavage of polyproteins ==== Some proteins and most eukaryotic polypeptide hormones are synthesized as a large precursor polypeptide known as a polyprotein that requires proteolytic cleavage into individual smaller polypeptide chains. The polyprotein pro-opiomelanocortin (POMC) contains many polypeptide hormones. The cleavage pattern of POMC, however, may vary between different tissues, yielding different sets of polypeptide hormones from the same polyprotein. Many viruses also produce their proteins initially as a single polypeptide chain that were translated from a polycistronic mRNA. This polypeptide is subsequently cleaved into individual polypeptide chains. Common names for the polyprotein include gag (group-specific antigen) in retroviruses and ORF1ab in Nidovirales. The latter name refers to the fact that a slippery sequence in the mRNA that codes for the polypeptide causes ribosomal frameshifting, leading to two different lengths of peptidic chains (a and ab) at an approximately fixed ratio.
=== Chemical === The chemistry of mendelevium is known largely in solution (as available quantities do not allow the creation of pure compounds), in which it can take on the +3 or +2 oxidation states. The +1 state has also been reported, but has not yet been confirmed. Before mendelevium's discovery, Seaborg and Katz predicted that it should be predominantly trivalent in aqueous solution and hence should behave similarly to other tripositive lanthanides and actinides. After the synthesis of mendelevium in 1955, these predictions were confirmed, first in the observation at its discovery that it eluted just after fermium in the trivalent actinide elution sequence from a cation-exchange column of resin, and later the 1967 observation that mendelevium could form insoluble hydroxides and fluorides that coprecipitated with trivalent lanthanide salts. Cation-exchange and solvent extraction studies led to the conclusion that mendelevium was a trivalent actinide with an ionic radius somewhat smaller than that of the previous actinide, fermium. Mendelevium can form coordination complexes with 1,2-cyclohexanedinitrilotetraacetic acid (DCTA). In reducing conditions, mendelevium(III) can be easily reduced to mendelevium(II), which is stable in aqueous solution. The standard reduction potential of the E°(Md3+→Md2+) couple was variously estimated in 1967 as −0.10 V or −0.20 V: later 2013 experiments established the value as −0.16±0.05 V. In comparison, E°(Md3+→Md0) should be around −1.74 V, and E°(Md2+→Md0) should be around −2.5 V.
== Experimental data == There have been various experiments elucidating the structure and function of LepA. One notable study is termed the "toeprinting experiment": this experiment helped to determine LepA's ability to back-translocate. In this case, a primer was extended via reverse transcription along mRNA which was ribosome-bound. The primers from modified mRNA strands from various ribosomes were extended with and without LepA. An assay was then conducted with both PRE and POST states, and cleavage studies revealed enhanced positional cleavage in the POST state as opposed to the PRE state. Since the POST state had been in the presence of LepA (plus GTP), it was determined that the strong signal characteristic of the POST state was the result of LepA which then brought the signal down to the level of the PRE state. Such a study demonstrated that that ribosome, upon binding to the LepA-GTP complex assumes the PRE state configuration.
Sources: en.wikipedia.org
Bukele's relationship with the FMLN began to deteriorate after he became mayor of San Salvador. He clashed with other party members on Twitter, and frequently resisted FMLN party leadership. Bukele became a strong critic of Salvador Sánchez Cerén, the FMLN president of El Salvador who was elected in 2014. He threatened to leave the party in 2015 if the FMLN-led government reappointed Luis Martínez as the country's attorney general, describing Martínez as "a gangster, very corrupt, [and] the worst of the worst". The FMLN relented and replaced Martínez, and Bukele later admitted that his threat to leave the party "was a bluff". In September 2017, San Salvador FMLN member Xóchitl Marchelli alleged that Bukele had thrown an apple at her, calling her a "damn traitor" ("maldita traidora") and a "witch" ("bruja"). Bukele did not attend an FMLN ethics tribunal on 7 October 2017, saying that the tribunal was biased in favor of Marchelli. On 10 October 2017, he was expelled from the party after the tribunal determined that he had engaged in "defamatory acts" ("actos difamatorios") against the party, showed "disrespect" ("irrespeto") for women's rights and the party's statutes, and made "disqualifying comments" ("comentarios descalificadores") to party members. Marchelli sued Bukele through the Specialized Investigative Court, but sent a letter to the court in October 2018 saying that she would no longer pursue the matter for health reasons. Despite Marchelli's withdrawal, the FGR proceeded with the case. On 29 March 2019, the Specialized Sentencing Court acquitted Bukele.
=== Other senior wins (6) === 1987 Northville Invitational (United States), German PGA Team Championship 1997 Dai-ichi Seimei Cup (Japan) 2000 Senior Skins Game (U.S. – unofficial event) 2009 Liberty Mutual Legends of Golf – Demaret Division (with Bob Charles) 2010 Liberty Mutual Legends of Golf – Demaret Division (with Bob Charles) *The Senior British Open was retroactively recognised by the PGA Tour Champions as a senior major in 2018.
== External links == Cobalt-60, Centers for Disease Control and Prevention. NLM Hazardous Substances Databank – Cobalt, Radioactive Beta decay of Cobalt-60, HyperPhysics, Georgia State University. Dr. Henry Kelly (March 6, 2002). "Cobalt-60 as a Dirty Bomb". Federation of American Scientists. Archived from the original on April 5, 2002. Retrieved November 26, 2005.
== Brand names == Aldonil (Zydus Medica), India Aldorin, Bangladesh Alrista (marketed and not manufactured by Macleods), India Epalrica-M (Ordain Global), India Eparel 50 (Microlabs Ltd), India Epimeth (Zaiva Lifesciences), India Eplistat 150 SR (Schem), India Letostat-SR (Amor Pharmaceuticals), India Listap-50 (Vivid Biotek), India Tanglin (Yangtze River Pharmaceutical Group), China
Sources: en.wikipedia.org
== See also == Great Famine (Ireland) Irish potato candy List of potato dishes List of potato museums Loy (spade), a form of early spade used in Ireland for the cultivation of potatoes New World crops Potato battery International Year of the Potato
== In popular culture == George Sessions Perry's 1941 novel Hold Autumn in Your Hand – and Jean Renoir's 1945 film adaptation of it, The Southerner – incorporates pellagra ("spring sickness") as a major plot element in the story of an impoverished Texas farm family. Satirical singer/pianist Tom Lehrer referred to pellagra as an endemic disease of the Southern states in the lyrics of his 1960 song "I Wanna Go Back to Dixie" -- "I'll go back to the Swanee / Where pellagra makes ya scrawny / And the honeysuckle clutters up the vine." Season 2, Episode 22 of House, titled "Forever", focuses on a new mother diagnosed with pellagra who experiences aggression and homicidal tendencies
=== Early history === The club traces its origins to a pair of clubs founded in 1904: Freiburger Fußballverein 04 was organised in March of that year; FC Schwalbe Freiburg just two months later. Both clubs underwent name changes, with Schwalbe becoming FC Mars in 1905, Mars becoming Union Freiburg in 1906, and FV 04 Freiburg becoming Sportverein Freiburg 04 in 1909. Three years later, SV and Union formed Sportclub Freiburg, at the same time incorporating the griffin head. In 1918, after World War I, SC Freiburg entered a temporary arrangement with Freiburger FC to be able to field a full side called KSG Freiburg. The next year, SC Freiburg associated themselves with FT 1844 Freiburg as that club's football department, until 1928 when they left to enter into a stadium-sharing arrangement with PSV (Polizeisportverein) Freiburg 1924 that lasted until 1930 and the failure of PSV. SC Freiburg then started again with FT 1844 Freiburg in 1938. The club played first in the Bezirksliga Baden in 1928, then in the Gauliga Baden, from which they were relegated in 1934. At the end of World War II, Allied occupation authorities disbanded most existing organizations in Germany, including football and sports clubs. The clubs reconstituted themselves after about a year, but were required to take on new names in an attempt to disassociate them from Nazis. SC Freiburg was therefore briefly known as VfL Freiburg. By 1950, French-occupation authorities allowed the clubs to reclaim their old identities. Finally, in 1952, SC Freiburg left FT Freiburg behind again.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.